Aeromonas species are renowned enteric pathogens with virulence determinants linked with human diseases, such as gastroenteritis, skin and soft-tissue, muscle infections, and septicemia,. Recent concern of resistance has emerged in this organism, especially the presence carbapenemases. We describe a case series of emerging carbapenem resistance Aeromonas species infection in our hospital in Cali, Colombia. We reported cases since 2012 to 2016. Clinical information was recollected from the medical charts and laboratory information. Phenotypic detection of resistance was identified using broth microdilution by g VITEK 2 system (bioMérieux). A multiplex qPCR assay was performed in 11 isolates to identify genes encoding carbapenemases (blaKPC, blaVIM, blaIMP, and blaNDM) In total, 79 hospitalized patients with Aeromonas species infections were studied, and of those 20 had phenotypic resistance to carbapenems (25%). From this resistant infection, 70% were healthcare-associated infections (HAI). Forty-five percent of the patients were immunocompromised. Mortality rate was 30%, and in bacteremic patients was 100%. Aeromona hydrophila was the most common specie (90%). Most patients received empirical treatment with meropenem and failed to this treatment. PCR amplifications show negative results for the carbapenemases analyzed. Emerging phenotypic carbapenem resistance infection has seen in our hospital, most as HAI. High mortality rate especially in immunocompromised patients and failure to empirical treatment with carbapenems were found. As the main carbapenemase tested were negative, carbapenem resistance could be attributed to an intrinsic metallo-β-lactamase, CphA encoded by the cphA gene, and/or possible hyperproduction of ampC βlactamase and porins expression. All authors: No reported disclosures.